Disclosures: Jacob Romano: Nothing to Disclose, Jessica Burnside: Nothing to Disclose, Giada Sebastiani: Novo Nordisk: Consultant, Abbvie: Speaking and Teaching, Merck: Consultant, Gilead: Speaking and Teaching, Theratechnologies Inc.: Grant/Research Support, Keyur Patel: Novo-Nordisk: Consultant, Gilead Sciences: Consultant, Merck: Consultant, Resalis: Advisor, Alnoor Ramji: Nothing to Disclose, Mark Swain: Ipsen: Advisor, Abbott: Advisor, Advanz: Advisor, Novo Nordisk: Advisor, GSK: Advisor, Ipsen: clinical trial research grant support, Novo Nordisk: clinical trial research grant support, Madrigal: clinical trial research grant support, Kowa: clinical trial research grant support, Gilead: clinical trial research grant support, Abbvie: clinical trial research grant support, Merck: clinical trial research grant support, Galectin: clinical trial research grant support, Sahar Saeed: Novo Nordisk: Consultant 1200 HELICOBACTER PYLORI CAGA/VACAS1-M1 STRAIN IS ASSOCIATED WITH HIGH RISK OF FIBROSIS IN METABOLIC-DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Fernando Barreyro 1 Facundo Maiorana 1 Magali Neschuk 1 Maria Viriginia Caronia 1 Karina Elizondo 2 Adolfo Schneider 2 Georgina Veron 2 Pedro Dario Zapata 1 , 1 National University of Misiones, 2 Barcelo University Institute of Health Sciences Background: Recent studies have suggested an association between H
The documentation process helps streamline access to the right care, without delays in treatment
If you do not own a calabash, you can prepare it in a French press
They reported that activation of the A1AR signaling pathway by N6-R-phenylisopropyladenosine (R-PIA) prevents hearing loss induced by cisplatin and OHC damage in the rat in vivo
20 , 116125.e115 (2022)
